The legal industry has been left permanently altered from the pandemic. Five thought leaders provide their exclusive take into what these changes look like from the inside
While WTO member states have expressed general sympathy for the goal to provide broad access to vaccine technology during the pandemic, Germany continues to favour patent protection over compulsory licensing.
The long read: Womble Bond Dickinson’s Ben Bourke takes a deep dive into how life science companies have handled their IP portfolios over the covid-19 pandemic – in particular Moderna Therapeutics’ pledge not to enforce patents relating to its vaccine – and examines how such adjustments can prepare the ground for future inventions
07 April 2021
A surge in life sciences applications offset a disappointing performance in other areas, the latest EPO statistics suggest
25 March 2021
“You could go through a practice of 30 years, never experiencing what we have just been through in a year,” says Julie Anne Gillespie in exclusive interview alongside colleague James Ryan
16 March 2021
Providing new insights into recent filings, but patent landscape uncertainties may pose dangers in the wake of the pandemic
09 March 2021
Concerns that rarely deployed Crown Use might become more commonplace have been significantly alleviated after appeals judges deliver ruling in IPCom v Vodafone
03 March 2021
Co-published - Although some major deals in the semiconductor space have been concluded over the last year, respondents to a survey on virtual negotiations see major difficulties in online discussions
02 March 2021
Preliminary figures also show a drop in PCT filings naming JPO as the receiving office
01 March 2021
Continued criticism of biopharma patent owners fails to acknowledge that manufacturing and supply complexities are the real obstacles to mass inoculation around the world
06 February 2021
Although the year was dominated by the response to covid-19, there were other major developments as well
30 December 2020
As non-patent assets become increasingly important, pharma and biotech innovators must adapt their IP strategies.
22 December 2020
Unlock unlimited access to all IAM content
